Aclidinium bromide for stable chronic obstructive pulmonary disease (Q24193506)

chronic obstructive pulmonary disease

title

Aclidinium bromide for stable chronic obstructive pulmonary disease (English)

0 references

main subject

0 references

author

Han Ni

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Zay Soe

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

2 June 2020

Soe Moe

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

2 June 2020

publication date

19 September 2014

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

2 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

CD010509

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Preference, satisfaction and errors with two dry powder inhalers in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

An update on the efficacy and safety of aclidinium bromide in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Domiciliary oxygen for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Self-management education for patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

The pathology of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Breathing exercises for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Tiotropium versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Pulmonary rehabilitation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Pathology, pathogenesis, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Influenza vaccine for patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Oral theophylline for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Lung volume reduction surgery for diffuse emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Smoking cessation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Oral corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

Aclidinium Bromide, a Long-Acting Antimuscarinic, Does Not Affect QT Interval in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010509.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD010509.PUB2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25234126 AND SRC:MED&resulttype=core&format=json

2 June 2020

1 reference